Eli Lilly’s dominant investment narrative is the rapid expansion of its GLP-1 franchise across diabetes, obesity, international markets, and oral formulations. Mounjaro and Zepbound have become the principal engines of growth. Mounjaro worldwide revenue increased 91% year over year to approximately $9.94 billion, exceeding the $8.99 billion consensus estimate, while U.S. revenue reached $4.8 billion versus expectations of $4.44 billion 21. Zepbound generated $4.93 billion in second-quarter revenue, with U.S. sales growth of 44% during the quarter and 58% in the first half, although lower realized prices partly offset demand 21,31.
The claims, published predominantly from August 5–13, 2026, describe a franchise that remains in a phase of exceptional growth but is moving beyond a supply-constrained launch cycle into a more demanding commercial period. Volume remains strong, international expansion is accelerating, and the oral obesity market appears additive rather than cannibalistic. The formulation is therefore commercially promising, but its future economics will depend increasingly on pricing concessions, manufacturing investment, Medicare access, product concentration, and the eventual arrival of generic or next-generation competitors.
Scientific and Commercial Foundation
Mounjaro is the central growth asset
The most strongly corroborated evidence supports an unusually steep Mounjaro trajectory. Revenue increased from $2.3 billion to $14.9 billion over ten quarters 9, while trailing-twelve-month sales reached approximately $32.5 billion by the second quarter of 2026, surpassing Ozempic’s $18.7 billion 10. Mounjaro’s trailing sales crossed Ozempic’s in 2025 and subsequently widened the gap 10.
Quarterly results show that international markets are now essential to the formulation of growth. International Mounjaro revenue reached $5.2 billion, above U.S. revenue of $4.8 billion 7, and non-U.S. sales increased 172% 21. As of the second quarter of 2026, most Mounjaro revenue was booked outside the United States 8. Lilly is consequently no longer relying solely on U.S. obesity demand; reimbursement, prescribing, and market access abroad have become substantial contributors.
International scale, however, carries a pricing trade-off. Adding Mounjaro to China’s National Reimbursement Drug List expanded access and volume but reduced realized prices 31. More broadly, the company’s realized prices fell 13% despite strong sales growth, while volume-based procurement in China limited pricing flexibility 29. Lilly can continue to compound revenue through volume and geographic expansion, but headline growth may increasingly overstate underlying price power.
Zepbound sustains obesity demand while monetization becomes more complex
Zepbound demand continued to increase and supported consecutive strong quarters 21. U.S. revenue grew 44% year over year in the second quarter and 58% during the first six months 31. Realized prices nevertheless declined because of previously announced cash-pay reductions and broader rebate or discount dynamics 21,31. Approximately 45% of total Zepbound prescriptions and 55% of new prescriptions were self-pay 30, consistent with the separate estimate that self-pay represented approximately 45% of total prescriptions 30.
This self-pay base is both an access mechanism and a source of economic sensitivity. It broadens the commercial opportunity, but revenue conversion depends on discounting, payer mix, and future reimbursement policy. The same products also create material concentration risk: Mounjaro and Zepbound together accounted for approximately 65% of quarterly revenue, while endocrinology products represented 74% 29. Lilly is therefore a high-top-line-growth company whose performance is strongly tied to weight-loss medicines 22. This concentration magnifies the benefit of continued incretin adoption, but it also increases the cost of any supply disruption, regulatory setback, competitive loss, or pricing deterioration.
Formulation Expansion and Category Development
Foundayo offers a new route into obesity treatment
Foundayo, Lilly’s oral obesity formulation of orforglipron, generated approximately $98 million during its initial commercialization period 25,29. The result was consistently reported across multiple claims, including second-quarter sales of $98 million against consensus estimates ranging from approximately $103 million to $104 million 17,19,20,21. Jefferies likewise described first-quarter sales as approximately $3 million below consensus 25, while Citi characterized the result as uninspiring and highlighted market-uptake risk relative to expectations 17.
The shortfall warrants caution rather than immediate dismissal. Foundayo launched only in the second quarter of 2026, and most international launches are expected in 2027 30. The product had already been approved in the United States and United Arab Emirates earlier in 2026 17, while many patients in Brazil, China, and India were reportedly paying out of pocket 21. Management’s view that the oral-treatment market is expansionary rather than cannibalizing Zepbound 21 is strategically important. Oral dosing could extend the addressable market, improve convenience, and create another channel for international growth.
The initial miss nevertheless places a demanding burden on subsequent execution. Investors should monitor prescription conversion, persistence, payer coverage, pricing, and the pace of international launches rather than apply the injectable growth curve directly to Foundayo.
The broader incretin category remains structurally favorable. U.S. incretin-analog prescription volume grew 31% in the second quarter of 2025 30, and sustained demand for GLP-1 medicines continues to be described as a driver of revenue and earnings growth 23. Retatrutide, a potential future competitor or market expander, is forecast by GlobalData to reach $15.2 billion in 2031 18, while alenoglipron was scheduled to enter late-stage development in the second half of 2026 26. These pipeline observations support the durability of the category, but they also establish the competitive standard Lilly must meet through differentiated efficacy, tolerability, convenience, supply, and access.
Manufacturing Capacity and Supply-Chain Integrity
Lilly faces manufacturing constraints as it expands production capacity 6. The company has incurred significant expenditures to increase capacity 29, and its updated guidance explicitly incorporates investment in manufacturing, pipeline development, and broader patient access 23. Full-year 2026 revenue guidance was raised to $85–$87 billion, while adjusted EPS guidance was narrowed to $35.50–$36.50 and its upper end was reduced 23.
This combination suggests that demand is not the primary constraint. The nearer-term earnings trade-off is the cost of converting demand into supply while funding the infrastructure required for a larger franchise. Supply was described as stable for Lilly’s Zepbound and Novo Nordisk’s Wegovy at the cited point in time 18, but pharmaceutical supply chains remain vulnerable. Approximately 86% of active pharmaceutical ingredients used in the United States are manufactured abroad, predominantly in India and China 14, and an energy or supply shock affecting overseas API sites could cause acute U.S. shortages 14.
Lilly’s U.S. manufacturing expansion is partly intended to reduce tariff exposure 25. Domestic capacity therefore has strategic value beyond incremental volume: it can protect continuity of supply, reduce trade-policy risk, and support access programs. The excipient is capital intensity, but the active ingredient is greater control over supply-chain integrity.
Competitive Context and Long-Term Risks
Novo Nordisk’s slowdown confirms relative momentum—and category risk
Lilly’s comparison with Novo Nordisk is favorable in growth terms, but it is not an unqualified victory for the category. Novo’s second-quarter Ozempic sales were approximately $4.85 billion, up only 5% year over year 25, while injected Wegovy sales were approximately $3.01 billion, up 1% 25. Oral Wegovy generated approximately $498 million 20,25, below the DKK3.6 billion analyst expectation and approximately 20% below Citi’s estimate 19,28.
Novo’s reported sales rose 3%, adjusted sales rose 7%, and its constant-currency full-year outlook ranged from flat growth to a 6% decline 19,28. An earlier forecast for a 4%–12% decline was improved to 0%–6% 20. By contrast, Lilly’s Mounjaro and Zepbound continued to record quarterly growth of 91% and 44%, respectively 23,31. This divergence supports Lilly’s competitive momentum and explains why its revenue outlook remains closely tied to the two products 6,23.
Novo’s experience is also a useful historical control. A leading GLP-1 franchise can move rapidly from hyper-growth toward pricing, access, and maturity pressures. Ozempic sales rose above $19 billion before flattening and easing to $18.7 billion 10. Trulicity peaked near $8 billion in 2023 and subsequently declined, while Rybelsus peaked at approximately $3.5 billion before easing 10. Tirzepatide’s cross-indication scaling across diabetes and obesity 9 is a significant advantage, but not a guarantee against saturation or substitution.
Portfolio breadth remains a strategic requirement
The second-quarter 2026 sector backdrop was generally constructive. Nine of the 25 largest drugmakers reported at least 10% year-over-year growth, while Teva was the only one to report a decline, at less than 1% 20. Amgen reported 10% revenue growth to $10.1 billion and adjusted EPS growth of 4% 32. Regeneron revenue increased 17% to $4.3 billion and adjusted EPS rose 11% to $14.29 2,20,32. Gilead, Johnson & Johnson, and Amgen reported second-quarter sales growth of 8%, 7%, and 9%, respectively 20. Sanofi’s revenue increased 16% year over year and 10% sequentially, driven by Dupixent 20, while Bristol Myers Squibb raised its Eliquis growth expectation to 20%–25% from 10%–15% 20.
These comparisons place Lilly within a broader period of pharmaceutical growth, but its rate and incretin dependence remain distinctive. Other companies benefit from more diversified portfolios or different growth drivers. AbbVie experienced four consecutive quarters of sales declines in 2023 after Humira biosimilar competition 20, while Amgen’s denosumab represented approximately 18% of revenue 32. Lilly’s concentration is more acute, making portfolio broadening and pipeline productivity central to long-term risk management.
The market structure is favorable to innovative products but adverse to incumbents as patents expire. GlobalData projects that the share of global drug sales under patent protection will fall from 12% in 2022 to 4% in 2030 16. Generic entry can cause revenue to decline quickly once exclusivity ends 34. Multiple generic companies have filed ANDAs for versions of Mounjaro and/or Zepbound 31. The claims do not establish approval timing or a legally effective loss-of-exclusivity date; the filings therefore indicate eventual competitive intent, not an immediate threat to Lilly’s 2026 sales trajectory.
Investment Implications
Lilly is best understood as a global obesity-and-diabetes platform rather than as a conventional diversified pharmaceutical company. The thesis rests on three mutually reinforcing pillars: continued prescription growth in the incretin class, successful international commercialization of Mounjaro, and expansion into oral therapy through Foundayo. Mounjaro’s international revenue already exceeds U.S. revenue 7, while Zepbound remains overwhelmingly U.S.-based, with approximately $4.9 billion of U.S. revenue and only $0.1 billion outside the country 7. This creates a useful strategic complement: Mounjaro supplies geographic diversification, while Zepbound provides concentrated exposure to the U.S. obesity market.
The central debate is not whether demand exists, but how much of that demand Lilly can convert into durable net revenue after discounts, government reimbursement, and capacity investment. Lower realized prices affected both Mounjaro and Zepbound 31. Medicare access, new incretin channels, and uptake timing remain important near-term variables 31. The Federal Bridge Program sets pricing for an Amazon Pharmacy Medicare GLP-1 offering and is scheduled to expire in 2027 12,13, creating a potential transition point for channel economics.
The appropriate analytical discipline is therefore to track net price, payer mix, prescription volumes, supply availability, and manufacturing spending alongside reported revenue growth. Lilly’s commercial execution and product momentum remain materially stronger than Novo Nordisk’s current trajectory, and the oral opportunity could extend category penetration. The medium-term formulation is less simple: with approximately two-thirds of revenue tied to Mounjaro and Zepbound 29, price compression and future competition could make the next phase of growth more capital- and access-intensive. The available claims do not provide sufficient valuation data to establish a target price. They support a positive fundamental bias, but only with increasingly demanding monitoring of launch productivity and net economics.
Peripheral Evidence and Scope Limitations
Several claims in the supplied cluster are peripheral to Lilly and should not be treated as direct evidence on the company. They concern Daiichi Sankyo’s $19.1 billion 2030 target versus $13.2 billion in fiscal 2025 sales, its four years of double-digit growth, and its 2% sequential second-quarter decline 20; Takeda’s last double-digit-growth quarter 20; Sandoz’s worldwide commercialization rights, biosimilar strategy, and access objective 16; acquisition accounting, consideration, and contingent payments 31; licensing economics involving royalties and milestones 15,31, including AlzeCure’s non-dilutive $10 million upfront payment and management commentary 15; and Sanofi’s expectation that Dupixent exclusivity extends beyond 2031 20.
Other peripheral claims cover Krystal Biotech’s Vyjuvek revenue, prescriber growth, reimbursement, launches, pricing accruals, and share-price reaction 4,25; Emergent BioSolutions’ revenue, Narcan weakness, impairment, restructuring, losses, and share-price decline 25; and Pfizer’s, GSK’s, AstraZeneca’s, AbbVie’s, Merck’s, BioNTech’s, and Johnson & Johnson’s share-price, market-capitalization, workforce, or portfolio observations 1,33,34.
Additional non-Lilly observations include Regeneron’s recovery and share-price pattern 32, Vertex’s recent growth 20, Astellas’ double-digit growth 20, the Colombian pharmaceutical market 11, U.S. stocks and bonds in 2022 3,5, the broader pharmaceutical-company definition 34, the ten-quarter analytical period 9, foreign-currency exposures and hedge accounting 31, insider transaction details 35, market capitalization and ranking of an unidentified analyzed company 27, technical levels and momentum for an unidentified company 29, an acquisition of Ventyx 31, a one-time benefit 31, and a historical financial-data presentation 24. Cross-trial comparability between Olatorepatide and Zepbound is also limited because the studies occurred in different countries 32. These claims provide context for the wider healthcare dataset but have low direct evidentiary value for Lilly.
Key Takeaways
- Mounjaro and Zepbound remain Lilly’s defining growth engine. Mounjaro revenue rose 91% year over year to approximately $9.94 billion, while the two products together generated roughly 65% of quarterly revenue 21,29.
- International Mounjaro expansion is a major differentiator. Second-quarter international revenue exceeded U.S. revenue, although China reimbursement and broader access initiatives are already pressuring realized prices 7,31.
- Foundayo is strategically important but not yet fully validated. Initial sales of $98 million were below consensus, making uptake, payer coverage, and 2027 international launches important catalysts and risks 17,19,30.
- The fundamental outlook is positive but increasingly execution-sensitive. Capacity investment, self-pay exposure, Medicare pricing, concentration, and eventual generic or next-generation competition should be monitored alongside headline revenue growth 6,13,23,30,31.